Literature DB >> 2396305

A study of the interaction between omeprazole and phenytoin in epileptic patients.

T Andersson1, P O Lagerström, P Unge.   

Abstract

This study was performed to determine the effect of omeprazole, given in therapeutically recommended doses, on the steady-state plasma levels of phenytoin in epileptic patients. Five men and three women of median age 34 years participated in the study. Steady-state plasma levels of phenytoin were measured once a week for 2 weeks before and after, respectively, and during 3 weeks of concomitant omeprazole treatment with 20 mg daily. Urinary excretion of phenytoin and its metabolite [5-(p-hydroxyphenyl)-5-phenyl-hydantoin] were determined before and at the end of the omeprazole treatment period. The steady-state plasma phenytoin levels as well as urinary excretion of phenytoin and its main metabolite were unchanged during omeprazole treatment. The results from this study suggest that concomitant omeprazole treatment in therapeutically recommended doses (20 mg daily) will not significantly affect the steady-state plasma levels of phenytoin in epileptic patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2396305     DOI: 10.1097/00007691-199007000-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  23 in total

1.  Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity.

Authors:  K A Bachmann; T J Sullivan; L Jauregui; J H Reese; K Miller; L Levine
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

2.  Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.

Authors:  T Andersson; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects.

Authors:  P A Soons; G van den Berg; M Danhof; P van Brummelen; J B Jansen; C B Lamers; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Theophylline steady state pharmacokinetics is not altered by omeprazole.

Authors:  A M Taburet; J Geneve; M Bocquentin; G Simoneau; C Caulin; E Singlas
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 6.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

7.  Omeprazole induces gastric permeability to digoxin.

Authors:  M Gabello; M C Valenzano; M Barr; P Zurbach; J M Mullin
Journal:  Dig Dis Sci       Date:  2009-06-10       Impact factor: 3.199

Review 8.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 10.  Omeprazole drug interaction studies.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.